SONN Sonnet BioTherapeutics Hold...

Nasdaq sonnetbio.com


$ 4.46 $ -0.06 (-1.37 %)    

Tuesday, 14-Oct-2025 17:12:21 EDT
QQQ $ 598.52 $ -4.01 (-0.67 %)
DIA $ 462.82 $ 2.03 (0.44 %)
SPY $ 662.50 $ -0.81 (-0.12 %)
TLT $ 90.63 $ 0.29 (0.32 %)
GLD $ 382.74 $ 2.70 (0.71 %)
$ 4.31
$ 4.20
$ 4.29 x 700
$ 4.47 x 100
$ 4.18 - $ 4.50
$ 1.08 - $ 19.30
399,107
na
29.11M
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 02-13-2025 12-31-2024 10-Q
4 12-17-2024 09-30-2024 10-K
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-Q
8 12-14-2023 09-30-2023 10-K
9 08-14-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 02-13-2023 12-31-2022 10-Q
12 12-15-2022 09-30-2022 10-K
13 08-15-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 02-08-2022 12-31-2021 10-Q
16 12-17-2021 09-30-2021 10-K
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 02-16-2021 12-31-2020 10-Q
20 12-17-2020 09-30-2020 10-K
21 08-14-2020 06-30-2020 10-Q
22 05-18-2020 03-31-2020 10-Q
23 03-19-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 03-30-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 03-31-2016 12-31-2015 10-K
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sonnet-biotherapeutics-q3-eps-095-misses-049-estimate

Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate...

 sonnet-biotherapeutics-announces-expansion-of-its-phase-1b2a-clinical-study-evaluating-the-combination-of-son-1010-with-genentechs-atezolizumab-in-patients-with-platinum-resistant-ovarian-cancer

Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients w...

 palantir-the-trade-desk-tilray-sonnet-biotherapeutics-and-tesla-why-these-5-stocks-are-on-investors-radars-today

U.S. stocks traded mostly flat on Monday as investors reacted to President Donald Trump's announcement of a 30% tariff on a...

 why-is-sonnet-biotherapeutics-stock-trading-higher-on-monday

Sonnet to merge with crypto-backed firm, forming Hyperliquid Strategies with $888 million in assets, plus HYPE blockchain tokens.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION